Candesartan

Generic Name: Candesartan

Brand Names: Atacand, Atacand Hct

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₀N_₆O_₃

CAS Number: 139481-59-7

Unique Ingredient Identifier: S8Q36MD2XX

Background: Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of candesartan cilexetil.

Indication: May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction an...

Associated Conditions: Hypertension, NYHA Functional Class II-IV Heart Failure

Associated Therapies: -

Clinical Trials

Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression

Phase 4

Terminated

Conditions: Depression
Hypertension

Interventions: Drug: Sertraline
Drug: Candesartan

First Posted Date: 2013-02-18

Last Posted Date: 2016-10-20

Lead Sponsor: Vanderbilt University

Target Recruit Count: 1

Registration Number: NCT01794455

Locations: 🇺🇸
Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States

Renal Response to Lower Body Negative Pressure in Pre-hypertensive States

Phase 4

Completed

Conditions: White Coat Hypertension
Hypertension
Obesity
Resistant Hypertension

Interventions: Other: Lower body negative pressure (LBNP)
Drug: Candesartan cilexetil

First Posted Date: 2012-11-27

Last Posted Date: 2017-05-24

Lead Sponsor: PD Dr. Grégoire Wuerzner

Target Recruit Count: 78

Registration Number: NCT01734096

Locations: 🇨🇭
Service of nephrology and hypertension, Lausanne, Switzerland

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

Phase 1

Completed

Conditions: Cardiorenal Syndrome (CRS)

Interventions: Drug: Placebo
Drug: Candesartan

First Posted Date: 2012-09-05

Last Posted Date: 2021-11-18

Lead Sponsor: Mayo Clinic

Target Recruit Count: 33

Registration Number: NCT01678794

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Phase 4

Conditions: Essential Hypertension

Interventions: Drug: Candesartan

First Posted Date: 2012-06-27

Last Posted Date: 2014-11-18

Lead Sponsor: Third Military Medical University

Target Recruit Count: 500

Registration Number: NCT01629225

Locations: 🇨🇳
Department of Cardiology, Daping Hospital, The Third Military Medical University, Chongqing, China

Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan cilexetil
Drug: Olmesartan/Amlodipin

First Posted Date: 2012-06-07

Last Posted Date: 2016-05-03

Lead Sponsor: Institut für Pharmakologie und Präventive Medizin

Target Recruit Count: 83

Registration Number: NCT01613209

Locations: 🇩🇪
Praxis Dr. Heinz, Bergisch-Gladbach, Germany
🇩🇪
Praxis Dr. Pohl, Dresden, Germany
🇩🇪
Praxis Dr. Reimer, Anderbeck, Germany

and more 9 locations

Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Candesartan cilexetil
Drug: Olmesartan medoxomil
Drug: Olmesartan/amlodipine

First Posted Date: 2012-06-04

Last Posted Date: 2017-02-23

Lead Sponsor: Institut für Pharmakologie und Präventive Medizin

Target Recruit Count: 88

Registration Number: NCT01611077

Locations: 🇩🇪
Praxis Dr. Reimer, Anderbeck, Germany
🇩🇪
Praxis Dr. Zemmrich, Berlin, Germany
🇩🇪
St.-Josefs-Hospital, Cloppenburg, Germany

and more 8 locations

Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker

Not Applicable

Conditions: Hypertension

First Posted Date: 2011-10-03

Last Posted Date: 2011-10-03

Lead Sponsor: Slovak Academy of Sciences

Target Recruit Count: 35

Registration Number: NCT01444833

Locations: 🇸🇰
Institute of Experimental Endocrinology, SAS, Bratislava, Slovakia

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy

Phase 2

Completed

Conditions: Breast Cancer
Heart Failure

Interventions: Drug: Metoprolol
Drug: Placebo
Drug: Candesartan

First Posted Date: 2011-09-14

Last Posted Date: 2014-10-22

Lead Sponsor: University Hospital, Akershus

Target Recruit Count: 130

Registration Number: NCT01434134

Locations: 🇳🇴
Akershus University Hospital, Lørenskog, Norway

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: Placebo
Drug: Azilsartan
Drug: Candesartan cilexetil

First Posted Date: 2011-02-03

Last Posted Date: 2011-02-03

Lead Sponsor: Takeda

Target Recruit Count: 926

Registration Number: NCT01289132

The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Fimasartan 60mg
Drug: Fimasartan 120mg
Drug: Candesartan cilexetil

First Posted Date: 2010-06-02

Last Posted Date: 2012-08-24

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 290

Registration Number: NCT01135212

Locations: 🇰🇷
KyungPook National University Hospital, Daegu, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy